fr   en

Browse by date
Or search by keyword
Date: 2010-07-22
Biotech partner: Algeta (Norway)
Pharma Partner: Bayer Schering Pharma (Germany)
Type of agreement: * manufacturing
* commercialization/ distribution
Compound: Alpharadin® (radium-223 chloride)
Disease area: cancer
Development phase: Phase III
Nature of the agreement: Algeta has concluded two agreements for the manufacture and supply of Alpharadin for future commercial sale. The signing of these agreements triggers a € 5 million milestone payment from Bayer Schering Pharma, Algeta’s development and commercial partner for Alpharadin since last year (See agreements)
The first agreement, with Bayer, provides that Algeta will be the exclusive supplier of Alpharadin for future commercial sale. The second agreement is related to the production of Alpharadin (See agreements)

Go back to previous page